# US 2003/0203901 A1 · Methods of modulating tyrosine protein kinase function with indolinone compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203901 A1
- Document ID: US20030203901A1
- Status: Published application
- Kind: A1
- Application number: 10/302,932
- Filed: 2002-11-25
- Published: 2003-10-30
- Earliest claimed: 1998-04-02
- Assignees: Sugen, Inc.
- Inventors: Peng Cho Tang; Li Sun
- Web page: https://patentgrep.com/patent/US20030203901A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 209/34: in position 2
- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

## Claims

### Claim 1

An indolinone compound having a structure set forth in formula I:
54
wherein
(A) Q is an optionally substituted oxindole moiety bonded with the rest of the molecule through position 3 of the oxindole ring; and
(B) T is a ring moiety having the structure set forth in formula III:
55
wherein
(a) R4, R5, R6, and R7 are independently selected from the group consisting of
(i) hydrogen;
(ii) saturated or unsaturated alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, trihalomethyl, carboxylate, nitro, ester, and a five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moiety, wherein said ring moiety is optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iii) an aromatic or heteroaromatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iv) an aliphatic or heteroaliphatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, ester, and an aromatic or heteroaromatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(v) an amine of formula —(X1)n1—NX2X3, wherein X1 is selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties and wherein n1 is 0 or 1, and wherein X2 and X3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties;
(vi) a nitro of formula —NO2;
(vii) a halogen or trihalomethyl;
(viii) a ketone of formula —(X4)n4—CO—X5, wherein X4 and X5 are independently selected from the group consisting of alkyl optionally substituted with halogen, trihalomethyl, carboxylate, nitro, ester, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring moieties are optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties and wherein n4 is 0 or 1;
(ix) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6, X7, and X8 and are independently selected from the group consisting of alkyl and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties and wherein n6 and n7 are independently 0 or 1;
(x) an alcohol of formula —(X9)n9—OH or an alkoxyalkyl moiety of formula —(X10)n10—O—X11, wherein X9, X10, and X11 are independently selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n9 and n10 are independently 0 or 1;
(xi) an amide of formula —(X12)n12—NHCOX13, or of formula —(X14)n14—CONX15X16, wherein X12 and X14 are each independently selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n12 and n14 are independently 0 or 1, and wherein X13, X14, X15, and X16 are each independently selected from the group consisting of hydrogen, alkyl, hydroxyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester;
(xii) a sulfonamide of formula —(X17)n17—SO2NX18X19, wherein X17 is selected from the group consisting of alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18, and X19 are independently selected from the group consisting of hydrogen, alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18 and X19 taken together form a five-membered or six-membered aliphatic or heteroaliphatic ring optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester, and wherein n17 is 0 or 1;
(xiii) an aldehyde of formula —(X20)n20—CO—H wherein X20 is selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n20 is 0 or 1;
(xiv) a sulfone of formula —(X21)n21—SO2—X22, wherein X22 is selected from the group consisting of hydroxide, saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties and wherein X21 is selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n21 is 0 or 1; and
(xv) a thiol of formula —(X23)n23—SH or a thioether of formula —(X24)n24—S—X25, wherein X23 and X24 are independently selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester, and wherein n23 and n24 are independently 0 or 1, and wherein X25 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester;
(b) X is selected from the group consisting of NX26, sulfur, SO, SO2, and oxygen, wherein X26 is selected from the group consisting of
(i) hydrogen;
(ii) saturated or unsaturated alkyl optionally substituted with a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said ring moiety is optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iii) an aryl optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iv) a sulfone of formula —SO2—X27, wherein X27 is selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties; and
(v) an acyl of formula —C(O)X28, wherein X28 is selected from the group consisting of hydrogen, saturated and unsaturated alkyl, aryl, and a five-membered or six-membered ring moiety;
c) ring Y is selected from the group consisting of five-membered, six-membered, and seven-membered aromatic, heteroaromatic, or non-aromatic rings, wherein said heteroaromatic ring contains a heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, and wherein said non-aromatic ring in combination with R4 optionally forms a carbonyl functionality;
(d) G, J, and L are selected from the group consisting of carbon and nitrogen; and
(e) T is bonded to the rest of the molecule at the position of the ring marked with an asterisk (*) in formula III.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q is selected from the group consisting of type Q oxindoles.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R4 and R5 are independently selected from the group consisting of
(i) hydrogen;
(ii) methyl, ethyl, propyl, and butyl groups optionally substituted with substituents selected from the group consisting of halogen, trihalomethyl, cyano, and nitro moieties;
(iii) an amine of formula —(X1)n1—NX2X3, wherein X2 and X3 are independently selected from the group consisting of hydrogen and optionally substituted saturated alkyl, and X1 is optionally substituted saturated alkyl, and wherein n1 is 0 or 1, or wherein X2 and X3 taken together form a five-membered or a six-membered aliphatic or heteroaliphatic ring, optionally substituted at a ring carbon atom or hetero atom with a substituent selected from the group consisting of methyl, ethyl, propyl, phenyl, and alkoxyphenyl;
(iv) a nitro of formula —NO2;
(v) a halogen or trihalomethyl;
(vi) a ketone of formula —CO—X4, wherein X4 is selected from the group consiting of methyl, ethyl, propyl, n-butyl, and t-butyl;
(vii) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6 and X7 are selected from the group conssiting of a bond, methylene, ethylene, and propylene, and wherein X8 is selected from the group consisting of methyl and ethyl, and wherein n6 and n7 are independently 0 or 1;
(viii) an amide of formula —NHCOX13, or of formula —CONX15X16, wherein X13, X15, and X16 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, and phenyl;
(ix) a sulfonamide of formula —SO2NX18X19, wherein X18 and X19 are independently selected from the group consisting of hydrogen, methyl, and ethyl;
(x) an alcohol of formula —(X9)n9—OH or an alkoxyalkyl moiety of formula —(X10)n10—O—X11, wherein X9, and X10 are independently selected form the group consisting of methylene, ethylene, and propylene, and wherein X11 is independently selected from the group consisting of methyl, ethyl, and propyl, and wherein n9 and n10 are independently 0 or 1;
(xi) a sulfone of formula —(X21)n21—SO2—X22, wherein X22 is selected from the group consisting of hydroxide, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl moieties, and wherein X21 is saturated alkyl, and wherein n21 is 0 or 1; and
(xii) a thioether of formula —(X24)n24—S—X25, wherein X24 is independently selected from the group consisting of methylene, ethylene, and propylene, and wherein X25 is independently selected from the group consisting of methyl, ethyl, propyl, and phenyl, and wherein n24 is 0 or 1.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R4 and R5 are independently selected from the group consisting of
(i) hydrogen;
(ii) methyl and ethyl;
(iii) an amine of formula —(X1)n1—NX2X3, wherein X2 and X3 are independently selected from the group consisting of hydrogen methyl and ethyl, and X1 is methylene or ethylene, and wherein n1 is 0 or 1, or wherein X2 and X3 taken together form an optionally substituted ring selected from the group consisting of
56
(iv) a nitro of formula —NO2;
(v) a halogen;
(vi) a ketone of formula —CO—X4, wherein X4 is selected from the group consiting of methyl and t-butyl;
(vii) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6 and X7 are selected from the group conssiting of a bond, methylene, ethylene, and propylene, and wherein X8 is selected from the group consisting of methyl and ethyl, and wherein n6 and n7 are independently 0 or 1;
(viii) an amide of formula —NHCOX13, or of formula —CONX15X16, wherein X13, X15, and X16 are each independently selected from the group consisting of hydrogen, methyl, and phenyl;
(ix) a sulfonamide of formula —SO2NX18X19, wherein X18 and X19 are independently selected from the group consisting of hydrogen, methyl, and ethyl;
(x) an alcohol of formula —(X9)n9—OH or an alkoxyalkyl moiety of formula —(X10)n10—O—X11, wherein X9, and X10 are independently selected form the group consisting of methylene, ethylene, and propylene, and wherein X11 is independently selected from the group consisting of methyl, ethyl, and propyl, and wherein n9 and n10 are independently 0 or 1;
(xi) a sulfone of formula —SO2OH; and
(xii) a thioether of formula —S-phenyl.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R6 and R7 are independently selected from the group consisting of
(i) hydrogen;
(ii) methyl, ethyl, propyl, and butyl groups optionally substituted with halogen, trihalomethyl, cyano, and nitro moieties;
(iii) an amine of formula —(X1)n1—NX2X3, wherein X2 and X3 are independently selected from the group consisting of hydrogen and optionally substituted saturated alkyl, and X1 is an optionally substituted saturated alkylene, and wherein n1 is 0 or 1;
(iv) a halogen or trihalomethyl;
(v) an alcohol of formula —(X9)n9—OH or an alkoxyalkyl moiety of formula —(X10)n10—O—X11, wherein X9, and X10 are independently selected form the group consisting of methylene, ethylene, and propylene, and wherein X11 is selected from the group consisting of methyl, ethyl, and propyl, and wherein n9 and n10 are independently 0 or 1.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R6 and R7 are independently selected from the group consisting of
(i) hydrogen;
(ii) methyl and ethyl;
(iii) an amine of formula —(X1)n1—NX2X3, wherein X2 and X3 are independently selected from the group consisting of hydrogen, methyl, and ethyl, and X1 is selected from the group consisting of methylene and ethylene, and wherein n1 is 0 or 1;
(iv) a halogen;
(v) a hydroxy —OH or an alkoxy moiety of formula —O—X11, wherein X11 is independently selected form the group consisting of methyl, ethyl, and propyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein Y is a six-membered aromatic or heteroaromatic ring.

### Claim 8 (depends on 6)

The compound of claim 6, wherein Y is a six-membered aliphatic or heteroaliphatic ring.

### Claim 9 (depends on 8)

The compound of claim 8, wherein Y forms a ring selected from the group consisting of optionally substituted
57

### Claim 10 (depends on 6)

The compound of claim 6, wherein G is nitrogen.

### Claim 11 (depends on 6)

The compound of claim 6, wherein J is nitrogen.

### Claim 12 (depends on 6)

The compound of claim 6, wherein L is nitrogen.

### Claim 13 (depends on 6)

The compound of claim 6, wherein X is nitrogen, optionally substituted with alkyl.

### Claim 14 (depends on 6)

The compound of claim 6, wherein X is selected from the group consisting of sulfur, SO, and SO2.

### Claim 15 (depends on 6)

The compound of claim 6, wherein X is oxygen.

### Claim 16 (depends on 6)

The compound of claim 6, wherein T is selected from the group consisting of type T aldehydes.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising
(i) a physiologically acceptable carrier, diluent, or excipient; and
(ii) a compound according to claim 1, or a salt thereof.

### Claim 18 (depends on 1)

A method of modulating the function of a protein tyrosine kinase with an indolinone compound according to claim 1, comprising the step of contacting cells expressing said protein tyrosine kinase with said compound.

### Claim 19 (depends on 18)

The method of claim 18, wherein said indolinone compound modulates the activity of said protein tyrosine kinase in vitro.

### Claim 20 (depends on 18)

The method of claim 18, wherein said protein tyrosine kinase is HER2.

### Claim 21 (depends on 1)

A method of identifying an indolinone compound according to claim 1 that modulate the function of protein tyrosine kinase, comprising the following steps:
(a) contacting cells expressing said protein tyrosine kinase with said compound; and
(b) monitoring an effect upon said cells.

### Claim 22 (depends on 21)

The method of claim 21, wherein said effect is a change or an absence of a change in cell phenotype.

### Claim 23 (depends on 21)

The method of claim 21, wherein said effect is a change or an absence of a change in cell proliferation.

### Claim 24 (depends on 21)

The method of claim 21, wherein said effect is a change or absence of a change in the catalytic activity of said protein tyrosine kinase.

### Claim 25 (depends on 21)

The method of claim 21, wherein said effect is a change or absence of a change in the interaction between said protein tyrosine kinase with a natural binding partner.

### Claim 26 (depends on 21)

The method of claim 21, comprising the following steps:
(a) lysing said cells to render a lysate comprising protein tyrosine kinase;
(b) adsorbing said protein tyrosine kinase to an antibody;
(c) incubating said adsorbed protein tyrosine kinase with a substrate or substrates; and
(d) adsorbing said substrate or substrates to a solid support or antibody;
wherein said step of monitoring said effect on said cells comprises measuring the phosphate concentration of said substrate or substrates.

### Claim 27 (depends on 1)

A method for treating a disease related to unregulated tyrosine kinase signal transduction, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 28 (depends on 1)

A method of modulating tyrosine kinase signal transduction comprising administering to a subject a therapeutically effective amount of a compound according to claim 1.

### Claim 29 (depends on 1)

A method of preventing or treating an abnormal condition in an organism, wherein said abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a protein kinase and a natural binding partner, wherein said method comprises the following steps:
(a) administering a compound of claim 1; and
(b) promoting or disrupting the abnormal interaction.

### Claim 30 (depends on 41)

The method of claim 41, wherein said organism is a mammal.

### Claim 31 (depends on 29)

The method of claim 29, wherein said abnormal condition is cancer.

### Claim 32 (depends on 29)

The method of claim 29, wherein said abnormal condition is selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, post-traumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's disease, endocrine disorders, vasospasm, cerebellar ataxia, and gastrointestinal tract disorders.

### Claim 33

An oxindole compound of formula V
58
wherein R8 is selected from the group consisting of
(i) saturated alkyl, optionally substituted with a substituent selected from the group consisting of alkoxy, trihalomethyl, nitro, and cyano moieties, provided that said alkyl is not methyl;
(ii) an amine of formula —(X1)n1—NX2X3, wherein X1 is selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties and wherein n1 is 0 or 1, and wherein X2 and X3 taken together form a 5-membered or 6-membered heteroaliphatic ring;
(iii) an iodine;
(iv) a ketone of formula —(X4)n4—CO—X5, wherein X4 and X5 are independently alkyl and wherein n4 is 0 or 1;
(v) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6, X7, and X8 and are independently selected from the group consisting of alkyl and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties and wherein n6 and n7 are independently 0 or 1;
(vi) an amide of formula —(X12)n12—NHCOX13, or of formula —(X14)n14—CONX18X16, wherein X12 and X14 are each independently selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n12 and n14 are independently 0 or 1, and wherein X13, X15, and X16 are each independently selected from the group consisting of hydrogen, alkyl, hydroxyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester; and
(vii) a sulfonamide of formula —(X17)n17—SO2NX18X19, wherein X17 is selected from the group consisting of alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18, and X19 are independently selected from the group consisting of hydrogen, alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18 and X19 taken together form a five-membered or six-membered aliphatic or heteroaliphatic ring optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and where n17 is 0 or 1.

### Claim 34 (depends on 33)

The oxindole compound of claim 33, wherein said oxindole compound is selected from the group consisting of
59 60

### Claim 35

An oxindole compound of formula VI
61
wherein R9 is selected from the group consisting of
(i) an amine of formula —(X1)n1—NX2X3, wherein X1, X2, and X3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties and wherein n1 is 0 or 1;
(ii) a nitro of formula —NO2;
(iii) a chlorine, bromine, or iodine;
(iv) a ketone of formula —(X4)n4—CO—X5, wherein X4 and X5 are independently selected from the group consisting of alkyl optionally substituted with halogen, trihalomethyl, carboxylate, nitro, ester, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring moieties are optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties and wherein n4 is 0 or 1;
(v) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6, X7, and X8 and are independently selected from the group consisting of alkyl and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties and wherein n6 and n7 are independently 0 or 1;
(vi) an amide of formula —(X12)n12—NHCOX13, or of formula —(X14)n14—CONX15X16, wherein X12 and X14 are each independently selected from the group consisting of alkyl and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and wherein n12 and n14 are independently 0 or 1, and wherein X13, X15, and X16 are each independently selected from the group consisting of hydrogen, alkyl, hydroxyl, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring is optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester; and
(vii) a sulfonamide of formula —(X17)n17—SO2NX18X19, wherein X17 is selected from the group consisting of alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18, and X19 are independently selected from the group consisting of hydrogen, alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18 and X19 taken together form a five-membered or six-membered aliphatic or heteroaliphatic ring optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and where n17 is 0 or 1.

### Claim 36 (depends on 35)

The oxindole compound of claim 35, wherein said oxindole compound is selected from the group consisting of
62

### Claim 37

An oxindole compound of formula VII
63
wherein R10 is selected from the group consisting of
(i) an aromatic or heteroaromatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, amide, and ester moieties;
(ii) an aliphatic or heteroaliphatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, ester, and an aromatic or heteroaromatic ring optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, trihalomethyl, carboxylate, nitro, and ester moieties;
(iii) an amine of formula —(X1)n1—NX2X3, wherein X1 is selected from the group consisting of saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties and wherein n1 is 0 or 1, and wherein X2 and X3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aromatic, heteroaromatic, or aliphatic ring moieties, or wherein X2 and X3 taken together form a 5-membered or 6-membered heteroaliphatic ring;
(iv) a nitro of formula —NO2;
(v) a bromine;
(vi) a ketone of formula —(X4)n4—CO—X5, wherein X4 and X5 are independently selected from the group consisting of alkyl optionally substituted with halogen, trihalomethyl, carboxylate, nitro, ester, and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties, wherein said ring moieties are optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester moieties and wherein n4 is 0 or 1;
(vii) a carboxylic acid of formula —(X6)n6—COOH or ester of formula —(X7)n7—COO—X8, wherein X6, X7, and X8 and are independently selected from the group consisting of alkyl and five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties and wherein n6 and n7 are independently 0 or 1;
(viii) a sulfonamide of formula —(X17)n17—SO2NX18X19, wherein X17 is selected from the group consisting of alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18, and X19 are independently selected from the group consisting of hydrogen, alkyl, five-membered or six-membered aromatic, heteroaromatic, aliphatic, or heteroaliphatic ring moieties optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, or ester, and wherein X18 and X19 taken together form a five-membered or six-membered aliphatic or heteroaliphatic ring optionally substituted with one or more substituents independently selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, nitro, and ester and where n17 is 0 or 1.

### Claim 38 (depends on 37)

The oxindole compound of claim 37, wherein said oxindole compound is selected from the group consisting of
64

### Claim 39

An oxindole compound, wherein said oxindole compound is selected from the group consisting of
65
